CRANFORD, N.J., Feb. 23,
2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
("Citius" or the "Company") (Nasdaq: CTXR), a late-stage
biopharmaceutical company dedicated to the development and
commercialization of first-in-class critical care products, today
announced its participation in two upcoming investor conferences.
Citius Chairman and CEO Leonard
Mazur will present at the BIO CEO and Investor
Conference on February 26-27,
2024, and the Sidoti Small-Cap Virtual Conference on
March 13-14, 2024.
BIO CEO and Investor Conference Details:
|
Presentation:
|
9:45
am ET on Tuesday, February 27,
2024
|
|
Location:
|
New York Marriott
Marquis, New York City
|
|
Registration:
|
Available on the conference website.
|
Sidoti Small-Cap Virtual Conference Details:
|
Presentation:
|
1:45 pm ET on
Wednesday, March 13, 2024
|
|
Location:
|
Virtual
|
|
Registration:
|
Available on the conference website.
|
|
1x1
meetings:
|
Requests available
through a Sidoti representative
|
|
|
About Citius Pharmaceuticals, Inc.
Citius Pharma is a late-stage biopharmaceutical company
dedicated to the development and commercialization of
first-in-class critical care products. The Company's diversified
pipeline includes two late-stage product candidates. At the end of
2023, Citius completed enrollment in a Phase 3 Pivotal superiority
trial of Mino-Lok®, an antibiotic lock solution to salvage
catheters in patients with catheter-related bloodstream infections.
Citius has recently resubmitted the Biologics License Application
for LYMPHIR™, a novel IL-2R immunotherapy for an initial indication
in the treatment of cutaneous T-cell lymphoma. Citius previously
announced plans to form Citius Oncology, a standalone publicly
traded company with LYMPHIR as its primary asset. LYMPHIR received
orphan drug designation by the FDA for the treatment of CTCL and
PTCL. In addition, Citius completed enrollment in its Phase
2b trial of CITI-002 (Halo-Lido), a
topical formulation for the relief of hemorrhoids. For more
information, please visit www.citiuspharma.com.
Investor Contact:
Ilanit
Allen
ir@citiuspharma.com
908-967-6677 x113
View original content to download
multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-upcoming-bio-ceo-and-sidoti-investor-conferences-302069457.html
SOURCE Citius Pharmaceuticals, Inc.